Mode
Text Size
Log in / Sign up

Preprint framework analysis suggests SIEVE improves compound prioritization over existing methods via simulations.

Preprint framework analysis suggests SIEVE improves compound prioritization over existing methods vi…
Photo by GuerrillaBuzz / Unsplash
Key Takeaway
Note that SIEVE framework improves compound prioritization in simulations; clinical evidence is lacking.

This source is a preprint describing a framework or methodology analysis focused on compound prioritization. The authors utilize simulations and analyses of real data to assess the SIEVE framework against existing methods. The primary outcome evaluated was the ability to improve compound prioritization relative to current approaches.

The analysis indicates that the SIEVE framework improves relative to existing methods. However, specific effect sizes, absolute numbers, and p-values or confidence intervals were not reported in this document. The study phase is not reported, and no specific population or sample size is provided, as the work relies on computational simulations rather than a defined patient cohort.

Safety data, including adverse events, tolerability, or discontinuations, were not reported. The authors note that follow-up duration was not reported. Funding or conflicts of interest were not reported. Because the evidence is based on simulations and the publication is a preprint, the certainty of these findings is limited. The authors do not overstate the results, acknowledging the preliminary nature of the work.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Motivation: Complex disorders arise from multiple genetic mechanisms, but most drug-prioritization methods treat each disorder as a single phenotype and therefore miss locus-specific therapeutic opportunities. Results: We present SIEVE, a framework that decomposes complex disorders into genetically localized subphenotypes and links GWAS summary statistics, reference expression, and perturbational transcriptional profiles to prioritize compounds that target locus-anchored disease mechanisms. SIEVE also constructs genetically calibrated mechanism vectors, projects away nonspecific expression programs using negative anchors, and aggregates evidence across cell lines, doses, and time points to produce robust drug rankings. Across simulations and analyses of real data, SIEVE improves compound prioritization relative to existing methods and shows that subphenotype-aware, genetics-guided modeling can sharpen therapeutic discovery in heterogeneous disorders. Availability and Implementation: R implementation: github.com/ericstrobl/SIEVE.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.